Cargando…

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib

Detalles Bibliográficos
Autores principales:	Lambertini, M., Punie, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Podcast
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910735/ https://www.ncbi.nlm.nih.gov/pubmed/33399081 http://dx.doi.org/10.1016/j.esmoop.2020.100018

Ejemplares similares

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC
por: Lim, K.H.J., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on upper GI tumours
por: Cardone, C., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update
por: Mariamidze, E., et al.
Publicado: (2021)

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
por: Matikas, A., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial
por: Kfoury, M., et al.
Publicado: (2021)

ESMO Open: news in breast cancer 2019
por: Lambertini, Matteo
Publicado: (2020)

ESMO Leaders Generation Programme: an alumni insight
por: Arruda, Leticia De Mattos, et al.
Publicado: (2018)

ESMO Open special series on new emerging targets in cancer immunotherapy
por: Lambertini, Matteo
Publicado: (2020)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Sacituzumab govitecan for breast cancer
Publicado: (2022)

Highlights in breast cancer from ASCO 2016
por: Cardoso, Fatima
Publicado: (2016)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Sacituzumab Govitecan: First Approval
por: Syed, Yahiya Y.
Publicado: (2020)

Highlights from the San Antonio Breast Cancer Symposium 2015
por: Jassem, Jacek
Publicado: (2016)

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE
por: Parker, Chris
Publicado: (2018)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology
por: Senkus, Elżbieta
Publicado: (2017)

Highlights in lung cancer in 2019
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Current highlights in lung cancer in 2021
por: Lim, K.H.J., et al.
Publicado: (2021)

ASCO highlights podcast: head and neck cancers
por: Merlano, Marco
Publicado: (2016)

Cancer genome: highlights of a Nature Medicine perspective
por: Voest, Emile
Publicado: (2016)

Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan
por: Prescott, Adam Ethan, et al.
Publicado: (2022)

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Recent advances in adjuvant therapy for patients with melanoma
por: Weber, Jeffrey
Publicado: (2018)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
por: Lang, Yitian, et al.
Publicado: (2023)

¡Yo soy yo! /
por: Lukela
Publicado: (2017)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
por: Vranic, Semir
Publicado: (2023)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Introducing the Metastatic Breast Cancer Project: a novel patient-partnered initiative to accelerate understanding of MBC
por: Parry, Marina
Publicado: (2018)

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
por: Michaleas, S., et al.
Publicado: (2022)

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
por: Cheng, Shao-Xian, et al.
Publicado: (2023)

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
por: Carey, Lisa A., et al.
Publicado: (2022)

Yo-Yo Ma in the LHC tunnel
por: Brice, Maximilien
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_482jjm1ccljr97v2m58e9kfe0u